Trial reportFrontiers in cellular and infection microbiology2025
Effect of probiotic lozenges on improvement in tympanometric classification within 12 weeks in children aged 3-6 years with adenoid hypertrophy and otitis media with effusion undergoing non-surgical management: a randomized controlled trial.
Trial report in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intravesically administered human defensin-5 ameliorates E. coli induced catheter associated-urinary tract infections in female SD rats.Archives of microbiology · 2026Article
- Molecular Characterization of the Middle Ear Microbiome in Pediatric Otitis Media with Effusion: Diagnostic and Clinical Implications.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Otitis media with effusion (OME) is common among children aged 3-6 years with adenoid hypertrophy. Restoring middle-ear ventilation and clearing effusion are key goals during non-surgical management, and tympanogram classification serves as the main clinical indicator. The probiotic Streptococcus salivarius K12 (SSK12) can colonize the upper airway and inhibit pathogens, yet randomized trials using tympanogram classification as the primary endpoint are limited. Objective: This study aimed to evaluate the effect of daily SSK12 lozenges (≥1×10 Methods: A single-center, randomized, double-blind, placebo-controlled RCT was conducted. All participants received standard non-surgical management and were allocated to either SSK12 or placebo lozenges for 12 weeks. The primary outcome was child-level tympanogram improvement ("B/C→A") at week 12. Secondary analyses included ear-level results, tympanometric parameter changes, audiometric outcomes, and nasopharyngeal microbiota profiles. Logistic regression, generalized estimating equations (GEE), and linear mixed-effects models were employed to estimate adjusted odds ratios (aORs), interaction terms, and time effects. Results: Compared with placebo, SSK12 significantly increased the probability of tympanogram improvement (aOR=1.87, P = 0.003), with consistent benefits across subgroups (all p(interaction)>0.05). Ear-level analyses confirmed the advantage (all aOR>1, P<0.05), with moderate intra-child correlation (ρ≈0.33). SSK12 produced significant group × time interactions for tympanometric parameters-positive changes in ΔTPP and ΔYtm and decreased ΔTW (all P<0.01). Microbiological analyses demonstrated a marked increase in SSK12 colonization (both rate and load, P<0.001) and reduced loads of H. influenzae, S. pneumoniae, and M. catarrhalis (all P<0.01). Audiological outcomes improved, including greater decline in four-frequency pure-tone average (P = 0.002) and higher DPOAE conversion (aOR=2.06, P = 0.001). Incidences of upper respiratory infections and acute otitis media were reduced (both P<0.05). No significant adverse effects or blinding bias were observed. Conclusion: Daily SSK12 lozenges for 12 weeks significantly improved tympanogram classification and auditory function, mediated by enhanced probiotic colonization and pathogen suppression, with excellent safety and adherence. SSK12 represents a low-risk, biologically rational adjunct in the conservative management of pediatric OME associated with adenoid hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.